Microglial activation decreases retention of the protease inhibitor saquinavir: implications for HIV treatment

Table 2 Effect of various signal transduction pathway inhibitors on [ ³ H]saquinavir accumulation in microglia

Inhibitor	Concentration	Saquinavir transport (% control)
		10 ng/ml LPS^a	Inhibitor alone	LPS + Inhibitor
Anti-TLR2	1 μg/ml	62 ± 2	99 ± 3	^b82 ± 2
Anti-TLR4	1 μg/ml	62 ± 2	99 ± 4	^b75 ± 3
Fucoidan	50 ng/ml	67 ± 3	92 ± 5	57 ± 2
DPI	10 nM	63 ± 2	94 ± 9	64 ± 11
Tempol	20 μM	63 ± 2	88 ± 7	60 ± 3
IL-1β RA	10 μg/ml	73 ± 2	102 ± 4	77 ± 3
Anti-IL-1β	0.5 μg/ml	63 ± 3	91 ± 2	64 ± 2
Anti-TNF-α	0.5 μg/ml	63 ± 3	89 ± 2	64 ± 2
TIMP3	10 ng/ml	57 ± 4	97 ± 5	61 ± 2
1400 W	5 μM	61 ± 3	94 ± 3	70 ± 2
L-NMMA	10 μM	58 ± 3	98 ± 7	63 ± 2
BIM	25 nM	61 ± 4	92 ± 3	67 ± 6
Wortmannin	1 μM	70 ± 2	99 ± 6	68 ± 3
SB203580	10 μM	63 ± 2	93 ± 2	63 ± 3
JNKII	10 μM	66 ± 3	96 ± 2	64 ± 3

Pathway inhibitor acronyms defined in text. ^a P < 0.05 as compared to untreated controls. ^b P < 0.05 as compared to LPS alone and untreated controls (partial inhibition).

ISSN: 1742-2094